Objective: Recent developments in micro-emulsification technology have allowed the fortification of foods with long-chain n-3 polyunsaturated fatty acid (PUFA) without the undesirable fish odour/taste and with reasonable shelf life. The effects of supplementing the diets of people with diabetes type II with a hummus-based dip enriched with long-chain n-3PUFA on plasma fatty acid composition and lipid levels were examined. Design: A pre-and post-intervention study. Setting: This study was conducted at the University of Newcastle, Australia. Subjects: Participants were recruited via advertisements on the University of Newcastle notice boards and in the local newspapers. Following initial response to study advertisements, information statements were mailed out to 29 potential participants. Thirteen participants were eligible and consented to participate in the trial. There were no dropouts as all the 13 participants completed 6-week intervention trial. Methods: Free-living male and female subjects with diabetes type II (n ¼ 13) consumed the n-3PUFA-enriched dip for a period of 6 weeks. Fasting blood samples were collected pre-and post-intervention for analyses of fatty acids and plasma lipids. Results: Following 6 weeks of consuming the enriched dip, all the long-chain n-3PUFA (20:5n-3, 22:5n-3 and 22:6n-3) were significantly (Po0.05) elevated in the plasma lipids. This represented an increase in 20:5n-3 content by 117%, an increase in 22:5n-3 content by 15% and an increase in 22:6n-3 content by 80% over the baseline values before dip consumption. A significant reduction (Po0.05) in the plasma triglyceride levels from 1.93 (1.08-2.09) mmol/l at baseline to 1.27 (0.93-2.22) mmol/l after 6 weeks was also apparent following the consumption of the n-3PUFA-enriched dip. Plasma cholesterol was unchanged; however, low-density lipoprotein (LDL)-cholesterol (2.4670.21 versus 2.7270.22 mmol/l, Po0.034) and highdensity lipoprotein (HDL)-cholesterol (1.1670.09 versus 1.2270.09 mmol/l, Po0.042) were significantly increased following the dietary intervention.
Introduction
Epidemiological and experimental evidence suggests that the consumption of long-chain n-3 polyunsaturated fatty acids (PUFA) is associated with a reduced risk of cardiovascular disease, certain types of cancer, inflammatory disease (rheumatoid arthritis, asthma, lupus and ulcerative colitis), diabetes mellitus, multiple sclerosis and clinical depression (He et al., 2004; Ruxton, 2004; Ruxton et al., 2004) . These effects are mediated by alterations in circulating lipid levels, eicosanoids, cytokines and physico-chemical properties of the cellular membranes (Balk et al., 2006; Mori and Woodman, 2006) . Long-chain n-3 fatty acids are pleiotropic molecules with a broad variety of biological actions including hypotriglyceridaemic, anti-aggregatory, anti-inflammatory and anti-arrhythmic responses.
The US Food & Drug Administration (FDA) has granted a qualified health claim for dietary n-3PUFA supplements: 'Consumption of o-3 fatty acids may reduce the risk of coronary heart disease. FDA evaluated the published data and determined that, although there is scientific evidence supporting the claim, the evidence is not conclusive ' (US Food and Drug Administration, 2004) . The UK has become the first country outside the US to grant an n-3 fish oil health claim that manufacturers throughout Europe have begun applying to their products. The claim, issued by the Joint Health Claims Initiative, made up of consumer protection groups, food law enforcers and members of the food industry, states: 'Eating 3 g weekly, or 0.45 g daily, longchain n-3 PUFA, as part of a healthy lifestyle, helps maintain heart health' (Joint Health Claims Initiative, 2005) . The importance of long-chain n-3PUFA as an essential nutrient for a healthy balanced diet has recently been recognized in Australia and New Zealand with their inclusion as a macronutrient recommendation in the draft document of nutrient reference values, previously known as recommended dietary intakes, which is due to be released shortly (National Health and Medical Research Council, 2006) .
Western diets fall well-short of the recommended two to three oily fish servings per week (Gregory et al., 1990; British Nutrition Foundation, 1992; Kris-Etherton et al., 2000 , 2002 Sugano and Hirahara, 2000; Meyer et al., 2003) . Food formulators have thus developed other ways of increasing fish oil intake, and a wide range of products, including eggs, breads, crackers, milks, cheeses and juices, is expected to carry a long-chain n-3PUFA health claim in the near future.
A hummus-based dip product containing long-chain n-3PUFA, using a micro-emulsification technique to mask the undesirable fish odour and taste, has been developed. The aim of the study was to investigate the bioavailability of n-3PUFA from the dip matrix and the associated effects on blood lipids and some other cardiovascular risk factors. The study involved people with diabetes type II because they are known to have elevated levels of plasma triglyceride, and dietary strategies to reduce triglyceride levels may be beneficial for the prevention of cardiovascular complications in these individuals (Lombardo and Chicco, 2006 ).
Materials and methods
The studies described herein were approved by the Human Research Ethics Committee of the University of Newcastle. Thirteen male and female participants with established diabetes type II were recruited via advertisement. Diabetic patients taking fish oil supplements or lipid-lowering medications were excluded. Participants were asked to refrain from eating seafood for at least 2 weeks before and during the 6-week intervention period. Following initial response to study advertisements, information statements were mailed out to 29 potential participants. Thirteen participants were eligible and consented to participate in the trial. There were no dropouts as all the 13 participants completed 6-week intervention trial.
All participants consumed 100 g/day of long-chain n-3PUFA-enriched dip for a period of 6 weeks. This dip provided 1.3-1.4 g of long-chain n-3PUFA/100 g. The dip contained healthy ingredients such as chickpeas as a base with added ingredients such as olives, sun-dried tomatoes, jalapeno and capsicum. The total fat content of the dip was 6.4-8.4 g/100 g, dependent on the added ingredients, with no more than 20% (1.3-1.7 g/100 g) of this as saturated fatty acids. Participants were given the choice of choosing a jalapeno-and/or an olive-flavoured dip.
Participants were instructed not to make any change in the type of foods that they normally consumed or in their level of physical activity during the study. Venous blood samples were collected at the start of the dietary intervention and following 6 weeks of dip consumption. Blood samples were centrifuged at 3000 g for 15 min to separate plasma from red blood cells. Plasma samples were analysed for plasma cholesterol, low-density lipoprotein (LDL)-cholesterol, highdensity lipoprotein (HDL)-cholesterol, glucose, glycosylated haemoglobin (Hb A1c ) and C-reactive protein (CRP) using standard analytical techniques.
Plasma fatty acid profiles were determined using an established method by Lepage and Roy (1986) . Frozen plasma samples were thawed at room temperature. To 100 ml of plasma, 2 ml of a methanol/toluene mixture (4:1 v/v), containing C21:0 (0.02 mg/ml) as an internal standard and butylated hydroxytoluene (0.12 g/l), was added and vortexed vigorously. Fatty acids were methylated by adding 200 ml of acetyl chloride dropwise whereas vortexing, followed by heating to 1001C for 1 h. After cooling, the reaction was stopped by adding 5 ml of 6% K 2 CO 3 followed by vigorous mixing by vortex. The sample was centrifuged at 3000 g at 41C for 10 min to facilitate separation of the layers. The upper toluene layer containing the fatty acid methyl esters was transferred to a 2 ml glass vial and crimp sealed with a Teflonlined cap for analysis by gas chromatography (GC).
GC analysis was conducted using a 30 Â 0.25 mm 2 (DB-225) fused carbon-silica column, coated with cyanopropylphenyl (J & W Scientific, Folsom, CA, USA). The temperatures of both the injector port and the detector port were set at 2501C (MacDonald-Wicks and Garg, 2004) . The oven temperature was 1701C for 2 min, increased by 101C/ min to 1901C, held for 1 min, then increased by 31C/min up to 2201C and maintained to give a total run time of 30 min. A split ratio of 10:1 and an injection volume of 3 ml were used. The chromatograph was equipped with a flame n-3 PUFA-enriched dip modulates plasma lipid profileionisation detector and an auto-sampler. Sample fatty acid methyl ester peaks were identified by comparing their retention times with those of a standard mixture of fatty acid methyl esters and quantified using a Hewlett Packard 6890 Series gas chromatograph with ChemStation software Version A.04.02. All participants weighed and recorded all foods and beverages consumed for a 3-day period at the commencement of and at the end of the 6-week intervention. Nutrient intakes were calculated using the Foodworks Professional Edition (version 3.02) software programme (Xyris Software Australia Pty Ltd, Brisbane, Australia).
Before statistical analysis, the data were assessed for linearity and homoscedasticity using the Scatterplot option and for normality using the Explore function of the Statistical Package for Social Sciences (SPSS), version 13.0 for Windows. The data were analysed using a paired t-test to compare means for each measurement at baseline with postdip consumption (SPSS version 13.0 for Windows). Data that were not normally distributed (including triglyceride and CRP concentrations and percentage Hb A1c ) were analysed by the Wilcoxon signed-ranks test, also using SPSS version 13.0 for Windows.
Results
Thirteen people with diabetes type II, 10 male subjects and three female subjects, were enrolled in the study. The average body weight was 62.2 kg and the average height was 171 cm. The diabetic state of the participants was confirmed by elevated fasting glucose (Table 1) . There was no change in body weight or the body mass index values following consumption of the dip for 6 weeks. The nutrient intakes remained unchanged during the 6-week intervention period (Table 2) . Energy intake was 9.6671.14 MJ/day before intervention and 8.9670.57 MJ/day post-intervention; protein intake was 99.376.8 and 94.976.1 g/day; carbohydrate intake was 291756 and 248729 g/day; total fat intake was 71.876.0 and 73.276.1 g/day, respectively. No differences were noted in the saturated (27.973.0 versus 28.071.8 g/day, respectively), monounsaturated (25.972.4 versus 27.573.5 g/day, respectively) and polyunsaturated (10.970.9 versus 11.371.6 g/day, respectively) fatty acid content before and following consumption of the long-chain n-3PUFA-enriched dip ( Table 2 ).
The dip provided 1.5-1.8 g/day of saturated (14:0, 6:0, 18:0, 22:0), 1.9-3.7 g/day of monounsaturated (16:1, 18:1 and 20:1), 1.6-1.7 g/day of n-6 (18:2, 18:3, 20:2 and 20:4) and 1.3-1.4 g/day of n-3 (18:3, 20:5, 22:5 and 22:6) fatty acids (Table 3 ) depending on the variety (jalapeno or olive flavour) of dip consumed. The dip was well-tolerated and the participants reported no adverse health effects consequent upon consuming 100 g of the dip daily for a period of 6 weeks.
Plasma cholesterol tended to be higher but not significantly so (4.4370.27 versus 4.6570.26 mmol/l, P ¼ 0.061) Figure 1 ). The ratio of plasma cholesterol to HDLcholesterol remained unchanged following 6-week consumption of the enriched dip. Plasma triglyceride values were significantly reduced (À0.25 mmol/l, P ¼ 0.038) by dip consumption (Table 1, Figure 1 ). Fasting glucose level, percentage Hb A1c and CRP concentration were not affected by the dietary intervention.
The fatty acid composition of the plasma lipids reflected the long-chain n-3PUFA enrichment in the dip matrix. All the long-chain n-3PUFA (18:3, 20:5, 22:5 and 22:6) were increased following 6-week consumption of the enriched dip (Table 4) . Saturated, monounsaturated and n-6 polyunsaturated fatty acids were not affected by the ingestion of the long-chain-n-3PUFA-enriched dip.
Discussion
Functional foods enriched with long-chain n-3PUFA that are currently available to consumers include breads, dairy products, eggs and meats. One of the limitations of these foods is that they need to be consumed in large quantities to meet a dietary recommendation of 200 mg/day for healthy adults or even in larger amounts to meet a dietary recommendation of 1000 mg/day of long-chain n-3PUFA for people at high risk of cardiovascular disease (Garg et al., 2006a, b) . We have developed a low-fat (total fat 6.4-8.6%), low-saturated fat (1.5-1.8 g/100 g), low sodium (o200 mg/ 100 g) humus-based dip containing relatively high amounts of long-chain-n-3PUFA using a micro-emulsification technique to mask the undesirable fish odour and taste. One tablespoon (20 g) of this dip is sufficient to meet daily requirements (200 mg/day) for healthy adults, and three to four tablespoons (75 g) can provide 1 g/day of long-chain n-3PUFA for people with cardiovascular risk factors. One hundred grams of the dip provides long-chain PUFA equivalent to the amount obtained from 4 Â 1 g of common brands of fish oil capsules. The aims of this study were to test n-3 PUFA-enriched dip modulates plasma lipid profile ML Garg et al the bioavailability of long-chain n-3PUFA from the dip matrix and to test the effectiveness of the dip enriched with long-chain n-3PUFA on plasma lipid levels. People with diabetes type II are known to have elevated levels of plasma triglyceride and dietary strategies to reduce triglyceride levels may be beneficial for the prevention of cardiovascular complications in these individuals (Lombardo and Chicco, 2006) . The results presented demonstrate that the longchain n-3PUFA present in the enriched dip was incorporated into the plasma lipids. The parent fatty acid of the n-3PUFA family (18:3n-3) was significantly lower in the plasma lipids following the dip intervention. This is likely to be a reflection of the foods, other than the dip, consumed during the intervention period as the fortified dip provided adequate amounts of 18:3n-3 (2.0% or 173 mg/100 g in the olive and 1.3% or 84 mg/100 g in the jalapeno-flavoured dip). Previous studies using fish oil capsules (containing long-chain n-3PUFA; 20:5n-3, 22%n-3 and 22:6n-3) as a supplement has not demonstrated such a change in plasma 18:3n-3 levels (Garg et al., 2006a, b) . Consumption of the dip was also accompanied by changes in the plasma lipid profile, typical of the effects of long-chain n-3PUFA when supplemented in capsule form.
As a major aim of the study was to demonstrate the uptake of long-chain n-3PUFA when consumed in a dip matrix, the fatty acid composition of the plasma total lipids was determined, because it represents incorporation into all lipid fractions including phospholipids, non-esterified fatty acids, triglycerides and cholesteryl esters. A 6-week intervention period was considered to be adequate to detect alterations in the plasma lipids and fatty acid composition and to provide evidence that up to 100 g/day of the enriched dip could be comfortably consumed by participants over that period of time. Participants reported no difficulties in consuming the amount of dip and reported favourably on the product. Two flavours of the dip were made available to the participants, which may have assisted in improved compliance. Compliance in the study, as determined by return of the empty containers and indeed evident from the fatty acid composition of plasma lipids, was 100%. The dip was well tolerated by the study participants with no detectable fishy odour/ eructation and no gastrointestinal disturbances reported as in the case of fish oil capsules (Kolanowski et al., 1999) .
Six-week consumption of the n-3PUFA-enriched dip had no adverse effects on glycaemia control, as evident by no significant (P40.05) change in fasting glucose or Hb A1c values. Low-grade sub-clinical inflammation, as determined by plasma levels of CRP, also remained unchanged following consumption of the dip. As CRP is also a common biomarker for obesity, diabetes and cardiovascular disease (Dandona et al., 2004) , it appears that the dip can be safely consumed by people with these conditions as there were no adverse effects of the dip on CRP levels.
Energy intake and percentage energy from protein, carbohydrate and fat remained constant during the study. Fibre and alcohol intake as well as saturated fat level in the diet remained unchanged during the 6-week intervention period. These results demonstrate that the effects on plasma lipids and fatty acid composition following dip consumption were specifically a consequence of the dip ingredients. Moreover, although the levels of physical activity were not determined, all the participants were clearly instructed not to alter their physical activities during the trial. Finally, none of the participants reported any change in medication over the 6-week intervention period. The total fat content of the participants' diet remained unchanged despite an additional 6.0-8.5 g of fat originating from 100 g of the long-chain n-3PUFA dip. Apparently, this oil intake was compensated for by adjustments in the fats consumed from other foods, indicating a replacement of possibly otherwise bad fats with healthy oil from the dip, keeping the total lipid intake constant as evident by increased, although non-significant, intake of monounsaturated and PUFA during the intervention period ( Table 2) .
Consumption of 1.3-1.4 g/day of long-chain n-3PUFA in the dip matrix for a period of 6 weeks resulted in a 35% reduction in the median plasma triglyceride values. A critical appraisal of 10 available randomized controlled trials addressing the efficacy of long-chain n-3PUFA as secondary agents for the prevention of hypertriglyceridaemia revealed that the average decrease in plasma triglyceride was 29% (Lewis et al., 2004) . Mechanisms for the reduction of plasma triglyceride involve a significant decrease in very LDL synthesis in the liver (Harris et al., 1997) and an increased triglyceride clearance as indicated by an increase in fractional catabolic rate (Simopoulos, 1999) . The results presented here suggest that the enriched dip may serve as a safe and effective alternative means of treating hypertriglyceridaemia, in lieu of lipid-lowering medications. The results presented are also consistent with a meta-analysis of 26 different trials in diabetic studies that showed that longchain n-3PUFA supplementation is associated with a significant decrease in plasma triglyceride in a dose-dependent manner (Friedberg et al., 1998) .
A small but statistically significant increase in LDL-cholesterol was noted following dietary supplementation with the long-chain n-3PUFA-enriched dip. This is consistent with published reports (Lu et al., 1999; Damsgaard et al., 2006) . A recent meta-analysis using a multivariate approach revealed that long-chain n-3PUFA supplementation increased total, LDL-and HDL-cholesterol (Castro et al., 2005) . In our study, total cholesterol was increased but the difference did not reach significance (P40.05), whereas HDL-cholesterol was significantly elevated following consumption of the dip for 6 weeks. The ratio of total cholesterol to HDL-cholesterol was not affected by the dietary intervention. The clinical significance of the increase in LDL-and HDL-cholesterol following n-3PUFA supplementation in some studies including this study, in the absence of no change in the ratio of total cholesterol to HDL-cholesterol, remains unclear.
n-3 PUFA-enriched dip modulates plasma lipid profileIn summary, short-term (6 weeks) consumption of a longchain n-3PUFA-enriched dip product allows incorporation of long-chain n-3PUFA into plasma lipids and exhibits the known lipid-modifying effects. Participants were asked to refrain from eating seafood for at least 2 weeks before and during the 6-week intervention period to ensure that the results obtained truly reflect the effects of the long-chain n-3PUFA dip supplement, not an artefact of the diet. However, this may have made the effects look stronger than it truly is, by creating an artificially low base-line plasma level of 20:5n-3 and 22:6n-3. Nevertheless, the developed functional food appears to be an ideal way to conveniently meet the dietary recommendation of 200 mg/day of longchain n-3PUFA (from just 20 g of the enriched dip) or even a recommendation of 450 mg/day (from 35 g of the enriched dip) as stipulated in the UK Health Claims guidelines. A larger longer-term placebo-controlled, randomized clinical trial is warranted to confirm the lipid-lowering potential of the enriched dip.
